Alterity Therapeutics Limited Asset Resilience Ratio
Alterity Therapeutics Limited asset resilience ratio. Alterity Therapeutics Limited (PBN) has an Asset Resilience Ratio of 16.30% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Alterity Therapeutics Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alterity Therapeutics Limited (2016–2025)
Asset resilience ratio of Alterity Therapeutics Limited from 2016 to 2025. This chart shows how Alterity Therapeutics Limited's Asset Resilience Ratio has changed over time. Read how much debt does Alterity Therapeutics Limited carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PBN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.50 Million | 16.3% |
| Total Liquid Assets | €7.50 Million | 16.30% |
Asset Resilience Insights
- Good Liquidity Position: Alterity Therapeutics Limited maintains a healthy 16.30% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Alterity Therapeutics Limited Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Alterity Therapeutics Limited Asset Resilience Ratio by Year (2016–2025)
Alterity Therapeutics Limited asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | €7.50 Million ≈ $8.77 Million |
€46.03 Million ≈ $53.81 Million |
-- |
| 2024-06-30 | 0.00% | €0.00 ≈ $0.00 |
€19.22 Million ≈ $22.47 Million |
-- |
| 2018-06-30 | 0.05% | €9.51K ≈ $11.12K |
€18.73 Million ≈ $21.89 Million |
-0.12pp |
| 2017-06-30 | 0.17% | €43.99K ≈ $51.43K |
€25.28 Million ≈ $29.56 Million |
-- |
| 2016-06-30 | 0.00% | €0.00 ≈ $0.00 |
€33.73 Million ≈ $39.43 Million |
-- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more